Midway through trading Monday, the Dow traded down 0.65% to 34,255.66 while the NASDAQ rose 0.41% to 14,126.79. The S&P also fell, dropping 0.23% to 4,237.53.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 33,462,280 cases with around 599,760 deaths. India confirmed a total of at least 29,510,410 cases and 374,300 deaths, while Brazil reported over 17,412,760 COVID-19 cases with 487,400 deaths. In total, there were at least 176,001,660 cases of COVID-19 worldwide with more than 3,805,010 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Information technology shares climbed 0.5% on Monday. Meanwhile, top gainers in the sector included Canaan Inc. CAN, up 26%, and Bit Digital, Inc. BTBT, up 27%.
In trading on Monday, materials shares fell 1.3%.
Accenture PLC ACN agreed to acquire Aachen, Germany's engineering consulting and services firm, umlaut.
The financial terms of the transaction remain undisclosed
Equities Trading UP
Enochian Biosciences, Inc. ENOB shares shot up 107% to $9.11. The FDA has accepted Enochian BioSciences Inc's pre-IND (Investigational New Drug) request for a potential functional cure or treatment of HIV.
Shares of RAPT Therapeutics, Inc. RAPT got a boost, shooting 115% to $39.95 as the company announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).
iTeos Therapeutics, Inc. ITOS shares were also up, gaining 39% to $27.78. iTeos Therapeutics and GlaxoSmithKline plc have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody.
Equities Trading DOWN
Washington Prime Group Inc. WPG shares tumbled 24% to $3.67 after the company filed for Chapter 11 bankruptcy.
Shares of Avenue Therapeutics, Inc. ATXI were down 33% to $2.8272 after the company received a second Complete Response Letter from the FDA regarding its marketing application seeking approval for IV tramadol.
Inhibikase Therapeutics, Inc. IKT was down, falling 22% to $4.66. Inhibikase Therapeutics filed for offering of up to 8 million shares of common stock.
In commodity news, oil traded up 0.8% to $71.47, while gold traded down 0.7% to $1,865.80.
Silver traded down 0.3% Monday to $28.075 while copper fell 0.1% to $4.5310.
European shares were mostly higher today. The eurozone’s STOXX 600 gained 0.18%, the Spanish Ibex Index rose 0.83% and the German DAX 30 fell 0.13%. Meanwhile, the London’s FTSE 100 gained 0.18%, French CAC 40 climbed 0.24% and Italy’s FTSE MIB rose 0.16%.
Eurozone industrial production increased 0.8% in April versus a revised 0.4% rise in the previous month.
There are no major economic released for Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.